#### PATENT COOPERATION TREATY

## **PCT**

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference SCB 904 PCT				FOR FURTHER A	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)			
1			lication No. 002190	International filing date 02.03.2005	ite (day/month/year)		Priority date (day/month/year) 25.03.2004	
	nation /. C07		ent Classification (IPC) or bo 9/00	oth national classification	and IPC			
	licant ENA	S.P.	A. et al.					
1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.							
2.	This REPORT consists of a total of 4 sheets, including this cover sheet.							
	This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).							
	These annexes consist of a total of 3 sheets.							
3.	This	repo	t contains indications rel	ating to the following i	tems:			
	1	$\boxtimes$	Basis of the opinion					
	П		Priority					
					novelty, in	ventive step ar	nd industrial applicability	
	IV		Lack of unity of invention					
	V	$\boxtimes$	Reasoned statement un citations and explanation	nder Rule 66.2(a)(ii) w ons supporting such st	ith regard atement	to novelty, inv	rentive step or industrial applicability;	
	VI		Certain documents cite		a.o.mom			
	VII		Certain defects in the in	nternational application	า			
	VIII		Certain observations or	n the international app	lication			
		-						
Date	Date of submission of the demand					completion of this	s report	
	07.11.2005					10.04.2006		
Name prelin	Name and mailing address of the international preliminary examining authority:					ed Officer	nethes Patenten	
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465			Baston Telephor	, E ne No. +49 89 23	399-8229			

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP2005/002190

I.	<b>Basis</b>	of the	re	port
----	--------------	--------	----	------

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	Description, Pages								
	1-1	1	as originally filed						
	Cla	Claims, Numbers							
	1-9		received on 07.11.2005 with letter of 07.11.2005						
2.	Wit lan	h regard to the <b>langu</b> guage in which the int	age, all the elements marked above were available or furnished to this Authority in the ternational application was filed, unless otherwise indicated under this item.						
	The	These elements were available or furnished to this Authority in the following language: , which is:							
		the language of a tra	anslation furnished for the purposes of the international search (under Rule 23.1(b)).						
		the language of pub	lication of the international application (under Rule 48.3(b)).						
		the language of a tra Rule 55.2 and/or 55.	anslation furnished for the purposes of international preliminary examination (under 3).						
3.	<b>otide and/or amino acid sequence</b> disclosed in the international application, the examination was carried out on the basis of the sequence listing:								
		contained in the inte	rnational application in written form.						
		filed together with th	e international application in computer readable form.						
		furnished subsequently to this Authority in written form.							
		furnished subsequer	ntly to this Authority in computer readable form.						
		The statement that the international a	ne subsequently furnished written sequence listing does not go beyond the disclosure pplication as filed has been furnished.						
		The statement that the listing has been furnitude.	ne information recorded in computer readable form is identical to the written sequence shed.						
4.	The	amendments have re	esulted in the cancellation of:						
		the description,	pages:						
		the claims,	Nos.:						
		the drawings,	sheets:						
5.		This report has been been considered to g	established as if (some of) the amendments had not been made, since they have go beyond the disclosure as filed (Rule 70.2(c)).						
		(Any replacement sh report.)	eet containing such amendments must be referred to under item 1 and annexed to this						
6.	Add	litional observations, i	f necessary:						

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP2005/002190

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1-10

1. Statement

Novelty (N) Yes: Claims

No: Claims

Inventive step (IS) Yes: Claims 1-10

No: Claims

Industrial applicability (IA) Yes: Claims 1-10

No: Claims

2. Citations and explanations

see separate sheet

## 10/593651

INTERNATIONAL PRELIMINARY
International application No. PCT/EP2005/002190

EXAMINATION REPORT - SEPARATE SHEET

#### To section V

The following documents were cited in the search report and were considered for the examination of the present application:

- D1: GB 809 913 A (CIBA LIMITED) 4 March 1959,
- D2: GB 868 478 A (LES LABORATOIRES FRANCAIS DE CHIMIOTHERAPIE) 17 May 1961,
- D3: SAKAI, S.I. OGAWA, M.: "The Chemical Transformation to Deserpidine" HETEROCYCLES, vol. 10, 1978, pages 67-71,
- D4: TAMIZ, A.P. ET AL.: "Structure-Activity Relationship for a ...Receptors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, 1999, pages 1619-1624.

The present application is directed to the preparation of Deserpidine, a natural product which is to be distinguished from Reserpine by the absence of a methoxy group in position 11. The process is characterized by the demethylation of a methoxy precursor (II) which results in the formation of a hydroxy intermediate (III), which is then reduced. Ring opening of the lactone and esterification results in the formation of the target molecule.

Document D4 deals with a demethylation process in general without mentioning intermediate (III). D1-D3 disclose preparation examples for Deserpidine. None of these documents uses a derivative bearing a methoxy group in position 11 which is then demethylated to a hydroxy intermediate according to formula (III). In view of this difference novelty is acknowledged for claims 1-7. Claims 8-9 are directed to intermediates with a hydroxy or a p-toluenesulfonate group in position 11, which are not anticipated by the prior art. Consequently claims 1-9 are novel (Art. 33(2) PCT).

None of the specified documents suggests the use of an intermediate (III) and thus the requirements of Art. 33(3) PCT are met.

Claim 1 was amended by incorporation of claim 2, thus clarifying that a precursor carrying a leaving group has to be present. The requirements of Art. 5 and 6 PCT are met.